Once-daily prolonged-release tacrolimus in De Novo liver transplantation: A single center cohort study

Shigeru Marubashi, Hiroshi Wada, Shogo Kobayashi, Hidetoshi Eguchi, Masahiro Tanemura, Koji Umeshita, Yuichiro Doki, Masaki Mori, Hiroaki Nagano

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aims: The feasibility of oral administration of once-daily prolonged-release tacrolimus (TAC-PR) in de novo liver transplantation is not clear and therefore was investigated further. Methodology: The clinical profiles of 16 consecutive primary living donor liver transplantation (LDLT) recipients, who received oral TAC-PR once daily (TAC-PR group) between January 2009 and August 2010, were compared with those of 14 consecutive liver transplantation recipients given twice-daily tacrolimus (TAC; TAC group) between August 2006 and January 2009. Of the 14 patients in the TAC group, 9 received LDLT (TAC-L subgroup). Results: Patient characteristics were similar between groups. Trough levels of TAC during the first 3 months after liver transplantation were well-adjusted in both groups. Dose adjustment was more frequently required (31.3%) in the TAC-PR group and the total amount of TAC was significantly higher in the TAC-PR group (181.1±75.3mg) than in the TAC-L group (100.2±53.8mg, p=0.014). The incidence of biopsy-proven acute cellular rejection, renal dysfunction, other morbidities and hospital stay length were similar between groups. Conclusions: Oral administration of TAC-PR for de novo liver transplantation recipients was well tolerated with similar safety and efficacy profiles as traditional twice-daily TAC with closely controlled adjustment of the TAC-PR dose.

Original languageEnglish
Pages (from-to)1184-1188
Number of pages5
JournalHepato-gastroenterology
Volume59
Issue number116
DOIs
Publication statusPublished - Jun 1 2012

Fingerprint

Tacrolimus
Liver Transplantation
Cohort Studies
Living Donors
Oral Administration
Length of Stay
Morbidity
Kidney
Biopsy
Safety
Incidence

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

Marubashi, S., Wada, H., Kobayashi, S., Eguchi, H., Tanemura, M., Umeshita, K., ... Nagano, H. (2012). Once-daily prolonged-release tacrolimus in De Novo liver transplantation: A single center cohort study. Hepato-gastroenterology, 59(116), 1184-1188. https://doi.org/10.5754/hge11623

Once-daily prolonged-release tacrolimus in De Novo liver transplantation : A single center cohort study. / Marubashi, Shigeru; Wada, Hiroshi; Kobayashi, Shogo; Eguchi, Hidetoshi; Tanemura, Masahiro; Umeshita, Koji; Doki, Yuichiro; Mori, Masaki; Nagano, Hiroaki.

In: Hepato-gastroenterology, Vol. 59, No. 116, 01.06.2012, p. 1184-1188.

Research output: Contribution to journalArticle

Marubashi, S, Wada, H, Kobayashi, S, Eguchi, H, Tanemura, M, Umeshita, K, Doki, Y, Mori, M & Nagano, H 2012, 'Once-daily prolonged-release tacrolimus in De Novo liver transplantation: A single center cohort study', Hepato-gastroenterology, vol. 59, no. 116, pp. 1184-1188. https://doi.org/10.5754/hge11623
Marubashi S, Wada H, Kobayashi S, Eguchi H, Tanemura M, Umeshita K et al. Once-daily prolonged-release tacrolimus in De Novo liver transplantation: A single center cohort study. Hepato-gastroenterology. 2012 Jun 1;59(116):1184-1188. https://doi.org/10.5754/hge11623
Marubashi, Shigeru ; Wada, Hiroshi ; Kobayashi, Shogo ; Eguchi, Hidetoshi ; Tanemura, Masahiro ; Umeshita, Koji ; Doki, Yuichiro ; Mori, Masaki ; Nagano, Hiroaki. / Once-daily prolonged-release tacrolimus in De Novo liver transplantation : A single center cohort study. In: Hepato-gastroenterology. 2012 ; Vol. 59, No. 116. pp. 1184-1188.
@article{6633cc2c67674de0806b3038197fa7c5,
title = "Once-daily prolonged-release tacrolimus in De Novo liver transplantation: A single center cohort study",
abstract = "Background/Aims: The feasibility of oral administration of once-daily prolonged-release tacrolimus (TAC-PR) in de novo liver transplantation is not clear and therefore was investigated further. Methodology: The clinical profiles of 16 consecutive primary living donor liver transplantation (LDLT) recipients, who received oral TAC-PR once daily (TAC-PR group) between January 2009 and August 2010, were compared with those of 14 consecutive liver transplantation recipients given twice-daily tacrolimus (TAC; TAC group) between August 2006 and January 2009. Of the 14 patients in the TAC group, 9 received LDLT (TAC-L subgroup). Results: Patient characteristics were similar between groups. Trough levels of TAC during the first 3 months after liver transplantation were well-adjusted in both groups. Dose adjustment was more frequently required (31.3{\%}) in the TAC-PR group and the total amount of TAC was significantly higher in the TAC-PR group (181.1±75.3mg) than in the TAC-L group (100.2±53.8mg, p=0.014). The incidence of biopsy-proven acute cellular rejection, renal dysfunction, other morbidities and hospital stay length were similar between groups. Conclusions: Oral administration of TAC-PR for de novo liver transplantation recipients was well tolerated with similar safety and efficacy profiles as traditional twice-daily TAC with closely controlled adjustment of the TAC-PR dose.",
author = "Shigeru Marubashi and Hiroshi Wada and Shogo Kobayashi and Hidetoshi Eguchi and Masahiro Tanemura and Koji Umeshita and Yuichiro Doki and Masaki Mori and Hiroaki Nagano",
year = "2012",
month = "6",
day = "1",
doi = "10.5754/hge11623",
language = "English",
volume = "59",
pages = "1184--1188",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "116",

}

TY - JOUR

T1 - Once-daily prolonged-release tacrolimus in De Novo liver transplantation

T2 - A single center cohort study

AU - Marubashi, Shigeru

AU - Wada, Hiroshi

AU - Kobayashi, Shogo

AU - Eguchi, Hidetoshi

AU - Tanemura, Masahiro

AU - Umeshita, Koji

AU - Doki, Yuichiro

AU - Mori, Masaki

AU - Nagano, Hiroaki

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Background/Aims: The feasibility of oral administration of once-daily prolonged-release tacrolimus (TAC-PR) in de novo liver transplantation is not clear and therefore was investigated further. Methodology: The clinical profiles of 16 consecutive primary living donor liver transplantation (LDLT) recipients, who received oral TAC-PR once daily (TAC-PR group) between January 2009 and August 2010, were compared with those of 14 consecutive liver transplantation recipients given twice-daily tacrolimus (TAC; TAC group) between August 2006 and January 2009. Of the 14 patients in the TAC group, 9 received LDLT (TAC-L subgroup). Results: Patient characteristics were similar between groups. Trough levels of TAC during the first 3 months after liver transplantation were well-adjusted in both groups. Dose adjustment was more frequently required (31.3%) in the TAC-PR group and the total amount of TAC was significantly higher in the TAC-PR group (181.1±75.3mg) than in the TAC-L group (100.2±53.8mg, p=0.014). The incidence of biopsy-proven acute cellular rejection, renal dysfunction, other morbidities and hospital stay length were similar between groups. Conclusions: Oral administration of TAC-PR for de novo liver transplantation recipients was well tolerated with similar safety and efficacy profiles as traditional twice-daily TAC with closely controlled adjustment of the TAC-PR dose.

AB - Background/Aims: The feasibility of oral administration of once-daily prolonged-release tacrolimus (TAC-PR) in de novo liver transplantation is not clear and therefore was investigated further. Methodology: The clinical profiles of 16 consecutive primary living donor liver transplantation (LDLT) recipients, who received oral TAC-PR once daily (TAC-PR group) between January 2009 and August 2010, were compared with those of 14 consecutive liver transplantation recipients given twice-daily tacrolimus (TAC; TAC group) between August 2006 and January 2009. Of the 14 patients in the TAC group, 9 received LDLT (TAC-L subgroup). Results: Patient characteristics were similar between groups. Trough levels of TAC during the first 3 months after liver transplantation were well-adjusted in both groups. Dose adjustment was more frequently required (31.3%) in the TAC-PR group and the total amount of TAC was significantly higher in the TAC-PR group (181.1±75.3mg) than in the TAC-L group (100.2±53.8mg, p=0.014). The incidence of biopsy-proven acute cellular rejection, renal dysfunction, other morbidities and hospital stay length were similar between groups. Conclusions: Oral administration of TAC-PR for de novo liver transplantation recipients was well tolerated with similar safety and efficacy profiles as traditional twice-daily TAC with closely controlled adjustment of the TAC-PR dose.

UR - http://www.scopus.com/inward/record.url?scp=84861366949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861366949&partnerID=8YFLogxK

U2 - 10.5754/hge11623

DO - 10.5754/hge11623

M3 - Article

C2 - 22172333

AN - SCOPUS:84861366949

VL - 59

SP - 1184

EP - 1188

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 116

ER -